Received Feb 6, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | 1 | EL9269 | SYR / RA |
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | 2 | EN6202 | SYR / LA |
The patient received the Pfizer-BioNTech COVID-19 vaccination, with Dose 1 administered on 02/08/2021 (Lot EL9269) and Dose 2 administered on 03/03/2021 (Lot EN6202). Cognitive symptoms, including memory loss, were first documented during primary care visits on 04/02/2024. Symptoms subsequently progressed. The patient was evaluated by neurology and diagnosed with early-onset Alzheimer?s disease on 10/16/2025. There is no known family history of early-onset dementia. The treating physician has indicated that a potential temporal association with COVID-19 vaccination cannot be ruled out. This report is submitted to document the event and its clinical timeline.
None
None
None
None
Primary care visits in 2024 documented complaints of memory loss (first documented 04/02/2024). Neurology evaluation resulted in a diagnosis of early-onset Alzheimer?s disease on 10/16/2025. Genetic testing performed on 02/04/2026 did not identify pathogenic variants associated with early-onset Alzheimer?s disease. See medical records for details.